WO2025146662 - CD1A-PD-1 BISPECIFIC AGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
National phase entry is expected:
Publication Number
WO/2025/146662
Publication Date
10.07.2025
International Application No.
PCT/IB2025/050090
International Filing Date
03.01.2025
Title **
[English]
CD1A-PD-1 BISPECIFIC AGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
[French]
AGONISTE BISPÉCIFIQUE DE CD1A-PD-1 POUR LE TRAITEMENT DE LA DERMATITE ATOPIQUE
Applicants **
IMMUNOCORE LIMITED
Inventors
CURNOCK, Adam
OVERTON, David
Priority Data
63/618,230
05.01.2024
US
63/716,619
05.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4986 | |
| EPO | Filing, Examination, Granting | 77525 | |
| Japan | Filing, Examination, Granting | 4462 | |
| South Korea | Filing, Examination, Granting | 6552 | |
| USA | Filing, Examination, Granting | 27790 |
Total:
121,315
Contact Us
Abstract[English]
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).[French]
La présente divulgation concerne des molécules à domaines multiples comprenant (i) un premier domaine de liaison qui se lie à PD-1, (ii) un second domaine de liaison qui se lie à CD1a et, éventuellement, (iii) un domaine d'extension de demi-vie. De telles molécules à domaines multiples sont particulièrement utiles dans le développement de réactifs immunothérapeutiques solubles pour le traitement de maladies auto-immunes, telles que la dermatite atopique (AD).